United States: Myriad - One Year Later

Last Updated: June 23 2014
Article by Thomas J. Engellenner

The Supreme Court decision last year on June 13, 2013 in Association of Molecular Pathology v. Myriad Genetics1 may have been a watershed moment for the biotechnology industry. So far the effects have been hard to detect, but don't be fooled. The storm is still brewing.

At the center of the controversy in the Myriad case was Myriad's so-called gene patents, which the Supreme Court struck down. The Court ruled that the isolation and identification of naturally occurring DNA sequences was unpatentable, even if the Myriad inventors were the first to realize these sequences correlated with aggressive forms of breast and ovarian cancers in patients. The Court concluded that the DNA sequences (known as the BRCA1 and BRCA2 genes) were ineligible for patent protection because they were products of nature.

Lurking behind the Court's decision was a different public policy issue: how to rein in health care costs. Myriad was a convenient target because its breast cancer predictive tests were so expensive (costing as much as $5,000 until a few years ago). Some viewed the decision as a political exercise, with the Supreme Court just doing its part to make sure breast cancer tests would be accessible and affordable. Ironically, the price of Myriad's assays had already started a downward spiral, and the Myriad patents at issue would have all expired by 2015 in any event.

Within days after the decision, Myriad's competitors, such as Ambry Genetics and Quest Diagnostics, issued press releases indicating that they would begin offering genetic testing for the BRCA1 and BRCA2 genes at a significantly reduced rate. Quest even initiated litigation to challenge Myriad's other patents that had not been before the Supreme Court.

Myriad put a brave face on following the decision, noting that the Court had also ruled that some of its DNA claims (directed to "complimentary DNA" or "cDNA") were valid because the sequences were synthetic and did not occur naturally.

Myriad's stock actually rose for a short period of time following the Supreme Court decision. However, a week later, Myriad's stock had fallen from $34 to $26 a share, with the company losing nearly one-quarter of its value.

In short order, Myriad sued Ambry and several other diagnostics companies, asserting infringement of these cDNA claims, as well as claims to DNA primers for amplifying BRCA genes, methods of making isolated BRCA genes by amplifying genomic DNA and methods of diagnosing or identifying individuals with a predisposition to breast cancer using Myriad's cDNA or primers. Myriad also filed counterclaims for patent infringement against Quest Diagnostics' declaratory action suit.

However, Myriad has encountered several setbacks in its legal battles against its competitors. Recently, the federal court handling the Ambry Genetics case refused to grant Myriad a preliminary injunction, ruling that Myriad had not demonstrated sufficient likelihood of success and the potential harm to Myriad (price erosion) did not outweigh the potential harm to Ambry (being put out of business). As of a few months ago, Myriad had at least five patent infringement suits pending in Utah, as well as several declaratory judgment actions (brought by competitors) in other states. Many of these cases are in the process of being consolidated in Utah before the same judge who denied Myriad the injunctive relief it sought against Ambry.

The price for Myriad's top-shelf BRCA1 and BRCA2 test has fallen, but it is expected to stay at or near today's level at least for the next year or so – when the last of its remaining basic patents expire. (In January 2014, Myriad negotiated a reimbursement price of about $2,000 per test from the Centers for Medicare and Medicaid Services; other insurers are likely to strike similar deals with Myriad.)

Oddly, the consequence of all this is that Myriad's stock price and market capitalization have risen back to the levels they were before the Supreme Court decision last year. Part of this is due to Myriad's transition to the more comprehensive "MyRisk" assay, which is predictive for a large number of hereditary cancer markers.

Myriad's competitors in the diagnostic arena (and biotechnology companies in general) are also doing well, although this may be a reflection of the currently bullish stock market. (Quest Diagnostics recently closed at about $60/share – only a few dollars less than its peak a year ago when the Myriad decision was handed down. Most of the other defendants in Myriad's suits are privately held, so information on their market capitalization and profits are not readily available.)

Although the full impact of the Myriad decision has not been felt so far, this may all change soon. Several recent court decisions provide some insight into how trial and appellate judges are interpreting Myriad.

Aria Diagnostics, Inc. v. Sequenom (N.D. California No. 11-CV-6391) involved a declaratory judgment suit brought by Aria (now known as Ariosa) to challenge Sequenom's patents, claiming methods of diagnosing prenatal issues by analyzing cell-free fetal DNA (cffDNA) in maternal blood. The federal district court that heard the case granted Aria's motion for summary judgment, finding that Sequenom's only invention was the discovery of the presence of cffDNA in maternal plasma, and that the detection of cffDNA using conventional techniques for DNA detection did not render the claim patent eligible. The case is currently on appeal to the Federal Circuit.

The case of In re Roslin Institute (Fed. Cir. No. 2013-1407, May 8, 2014) involved an appeal from a U.S. Patent Office decision not to allow claims to "cloned mammals." The Roslin Institute created Dolly the cloned sheep, among other things. The Court of Appeals for the Federal Circuit sustained the Patent Office position that a cloned mammal was still a product of nature insofar as Roslin "did not create or alter any of the genetic information" of its clones.

On March 4, 2014, nine months after the Supreme Court's Myriad decision, the U.S. Patent Office announced guidance based on the Myriad decision for patent examiners working on biotech patent applications. (Many interested parties objected to the issuance of "guidance" as an underhanded way for a federal agency to implement a major policy change, since, unlike federal rules and regulations, there is no requirement for a public comment period prior to implementation.)

Reading the Myriad decision broadly, the Patent Office guidelines set forth a three-stage inquiry and a 12-factor analysis to determine whether biotechnology patent applications are claiming patent-eligible subject matter. The guidance gave numerous hypothetical examples of claims and was accompanied by a training slideshow that elaborated on the examples.

The Patent Office guidelines were immediately criticized as going beyond the holdings of the Myriad case (as well as a related case decided by the Supreme Court the year before, Mayo Collaborative Services v. Prometheus Laboratories, No. 10-1150 (2012)). For example, the hypothetical example of amazonic acid (derived from the leaves of an imaginary Amazonian cherry tree) in the guidance has been roundly criticized for its conclusion that claims to purified amazonic acid would be unpatentable – despite the hypothetical fact that one teaspoon of such purified products would yield the same medicinal effect as eating 30 pounds of leaves.

Similarly, according to the guidance, claims to methods of treatment with purified amazonic acid were also ineligible for patent protection unless they also included very narrow limits on dosages and outlined very specific periods of time for administering the Amazonian cherry tree drug.

Others have objected to the proposed guidance for Patent Office examiners because of the emphasis on the need to reject any broad claim that might substantially foreclose others from using or applying a product of nature or natural principle in other ways.

In many ways, the PTO guidance fulfills the dire predictions made by industry groups that filed amicus briefs when the Myriad case was before the Supreme Court. A brief submitted by BIO, an industry group, identified several patented inventions that would be ensnared by rules prohibiting the patenting of isolated biological materials: vaccines (derived from live viruses), antibiotics (isolated from bacteria, fungi or soil samples), insulin, human growth hormones and a slew of industrially or therapeutically useful enzymes.

A particularly controversial aspect of the PTO's new policy is the test for claims involving a product of nature. According to the guidance, the examiner must ask himself or herself whether the claimed invention is "marked" or "significantly" different from the natural product itself. To put this in the context of the PTO's own examples, a pill containing purified amazonic acid is not markedly different than consuming 40 pounds of plant leaves. The Supreme Court's decision in the Myriad case does not support this sweeping "markedly different" standard. In fact, in its ruling, the Court made it very clear that the ruling was limited to DNA: "We merely hold that genes and the information they encode are not patent eligible under §101 simply because they have been isolated from the surrounding genetic material."

In the real world, purified compositions derived from natural products do indeed have properties different from their natural counterparts, e.g., they are not only more potent but also typically free of associated molecules that affect their solubility, speed of uptake, and specificity. In the end, the PTO guidance will probably just shift the analysis to arguments as to how "different" the claimed invention is from a natural ancestor – and the problem will be that the "markedly different" standard is entirely subjective, allowing examiners to reach varied and contradictory conclusions.

The PTO guidance also creates the anomaly that even a trivial change from the natural product can bestow patent eligibility to a composition.

Although the PTO has agreed to accept public comments on the guidelines until June 30, 2014, it seems unlikely that the guidance will be suspended or substantially changed. The biotechnology industry and patent practitioners should brace themselves for a long battle over whether the PTO's new policies are correct and workable.

Footnote

1 Pepper Hamilton examined the issues in this case while the world was awaiting the ruling, in our May 22, 2013 Client Alert, "The Curious Case of Human Gene Patents."

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions